ArticleHaematologica2019

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Alessandro M Vannucchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.